MarketPulse

biomarker

5 articles
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Biogen and Denali Halt BIIB122 Development After Phase 2b Parkinson's Study Fails

Biogen and Denali's LRRK2 inhibitor BIIB122 missed primary and secondary endpoints in Phase 2b Parkinson's trial. Companies discontinue development in idiopathic disease.
BIIBDNLIclinical trial failuredrug development
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Design Therapeutics Reports Positive Four-Week Data for Friedreich Ataxia Treatment

Design Therapeutics announces positive Phase 1/2 data for DT-216P2 showing clinical improvements and biomarker activity in Friedreich ataxia patients.
DSGNclinical trialgene therapy
GlobeNewswire Inc.GlobeNewswire Inc.··Medicinova, Inc.

Study Validates MediciNova's Brain Metastasis Drug as Cancer Research Advances

MediciNova's drug candidate gains validation in peer-reviewed Cancer Research study, with CNIO identifying MIF signaling as brain metastasis target and potential CSF biomarker for patient stratification.
MNOVbiomarkerbrain metastasis
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Pliant Therapeutics' PLN-101095 Shows Promise in Hard-to-Treat Cancer Patients

Pliant Therapeutics presented Phase 1 data for PLN-101095 showing 89% average tumor reduction in ICI-refractory cancer patients, with Phase 1b expansion underway.
PLRXimmunotherapyPhase 1 trial
GlobeNewswire Inc.GlobeNewswire Inc.··Na

Sagimet Biosciences Unveils MASH Trial Data, Secures Nasdaq Approval for Employee Equity Grant

Sagimet presented Phase 2b denifanstat data showing bile acid biomarker potential in MASH patients, while securing Nasdaq approval for employee stock options.
SGMTclinical trial dataMASH